Research & Development: Page 74
-
PharmaVoice Team/PharmaVoice
Letter from the Editor
3 PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, ...
By Taren Grom • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Nose Knows
Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceut...
By Taren Grom • Oct. 23, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
PharmaTrax
$7 Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS by 2005 The market for drugs employing advanced drug delivery technologies will surpass $7 billion by 2005,according to a study from Kalorama Information.The market segment has seen doubledigit growth over the past few years, and ...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
Despite a history of new product launches, strong growth, and increased research spending, it is clear that the pharmaceutical industry is in a period of major transition. The challenge facing the industry is one of creating a sustainable pipeline that can generate the longterm growth needed to f...
By Kevin Starr • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Table of Contents
on the cover High Stakes: HITECH The pharma industry could come out a winner in the new game of HITECH (Health Information Technology for Economic and Clinical Health Act), if companies can come up with the right ante. FEATURES Publication Planning Update Title VIII of FDAAA, which requires the p...
By PharmaVoice Team • Sept. 30, 2009 -
PharmaVoice Team/PharmaVoice
Christine Bunt: Converging on a Solution
Converging on a Solution Moving from diagnostics to pharmaceuticals, from Europe to the United States, and ultimately from big pharma to a small startup company is not for everybody. But Christine Bunt has the confidence, knowledge, and business acumen to take on any challenge, and she revels in ...
By Kim Ribbink • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
Last Word
AstraZeneca’s Dr. Larry Furlong Outlines the Company’s Lean Sigma Program for Process Improvement AstraZeneca is applying the business improvement methodology Lean Sigma to discovery in an attempt to shorten project lead times and increase candidate quality. AstraZeneca’s Larry Furlong, Ph.D., i...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Per FALK Novo Nordisk Names Clinical Research Head for North America Novo Nordisk, a global healthcare company focusing on diabetes care, has appointed Per Falk, M.D., Ph.D., as VP for clinical, medical, and regulatory affairs for North America. Dr. Falk leads clinical res...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Inclinical, Terrosa Offer Collaborative CTMS Subscription Services Pharsight Offers PK Data Management Solution Compass Healthcare Leverages Social Media in Community Website IMS Health Speeds Access to Promotiona...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: FDA Anticounterfeiting Draft Guidance Focuses on Chemical Identifiers inVentiv Renames Professional Development Business PCE Partners with ACU on Continuing Education for NPs, PAs Gullapalli Launches Patient-Centered CME Of...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Life-Sciences Companies Unprepared for Information Security Risks Despite the promise of the information age and the billions of dollars in economic stimulus funding, many life-sciences and healthcare companies have yet to mee...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009 -
PharmaVoice Team/PharmaVoice
Patient Recruitment: Strategies for Multinational Studies
Finding appropriate study subjects is still one of the biggest stumbling blocks for timely and efficient drug development. Recruiting patients for multinational trials can be even more daunting, since global trials add to the complexity. While experts say some issues are no longer an obstacle — s...
By Denise Myshko • Aug. 21, 2009 -
PharmaVoice Team/PharmaVoice
Last Word
Making the Connection How does the diversity program alliance between Centocor and the University of Michigan align with J&J’s overarching diversity programs? Barbosa: Within Centocor, as well as across Johnson & Johnson, there are fundamental principles that define the company and how we...
By PharmaVoice Team • Aug. 21, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
talent pool executive appointments and promotions in the healthcare industry Pharmaceutical POOL Dr. Ann MILLER Steven SEMBLER Eisai Appoints Two Senior VPs Eisai Inc. has expanded its leadership roster with the hiring of two senior VPs. Ann Miller, M.D., joins Eisai as senior VP, primary care an...
By PharmaVoice Team • Aug. 21, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Biopharma Firms Increasingly Seek Marketing Role in Licensing Deals Large pharmaceutical companies’ growing reliance on alliances and in-licensing to gain access to technologies and new molecular entities from biopharmaceutical firms has strengthened the bargaining position for firms offering the...
By PharmaVoice Team • Aug. 21, 2009 -
PharmaVoice Team/PharmaVoice
Raise Your Voice: Letters
Pricing: At What Cost In your March 2002 article “The Cost of Doing Business,” I criticized as incorrect the conclusion that high R&D costs cause high pharma prices. A more economically sensible conclusion is that high pharma prices cause companies to undertake higher cost, more diffi cult, a...
By PharmaVoice Team • Aug. 13, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Diane Hoffman Virginia Kirk Denise Myshko Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, Num...
By Taren Grom • Aug. 13, 2009 -
PharmaVoice Team/PharmaVoice
The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Mark Eisenach — The Mark of a Leader
With more than 75% of all clinical trials failing to meet enrollment deadlines, costing drug makers more than a million dollars a day in potential sales, Mark Eisenach’s mission is to help solve the industry’s chronic problem surrounding patient and investigator recruitment. Mark LEADER of a T...
By Kim Ribbink • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Vanlev: Coming Soon
In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Ribotsky Worldwide Inc., a fullservice communications company, has expanded its offerings to clients through a new division. Strategic Healthcare Solutions provides healthcare markettrends analy sis, competitive market and brand analysis, and healthcare marketcommunications analysis. Strate gic H...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
In a nod to the founding fathers, several states have started a revolution against the tyranny of high margin pharmaceuticals with the uninsured elderly playing the role of constituents deprived of their rights. This time the battlefield is the U.S. courts, and lawyers representing both sides are...
By Don Sharpe • Aug. 11, 2009 -
PharmaVoice Team/PharmaVoice
What's on your mind: Opinions
The Time Has Come The idea of setting up a separate agency to oversee postmarketing surveillance has been proposed over the past two to three decades — perhaps now its time has come. I would endorse using a new source of user funds to establish a quasiautonomous agency separate from FDA and indus...
By PharmaVoice Team • Aug. 11, 2009 -
PharmaVoice Team/PharmaVoice
Who's on the List by Section
The Commanders & Chiefs 12 Ahsan Awan Ross Bjella Laurie Cooke, R.Ph. John Farinacci Tuan Ha-Ngoc Fred Hassan Thomas Hughes, Ph.D. Greg Johnson Rick Keefer Kyle Kennedy William Maichle John Maraganore, Ph.D. Francois Nader, M.D. Nader Naeymi-Rad Angus Russell Laurent Schockmel, DVM Jeffrey St...
By PharmaVoice Team • July 30, 2009
Previous
